Trial: 201704073

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer (EAI142)

Phase

II

Principal Investigator

Dehdashti, Farrokh

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov